For many people thought to be at risk of developing Alzheimer’s disease, the uncertainty of knowing whether they will develop the disorder in the future is a significant source of anxiety. Melissa Murray, PhD from the Mayo Clinic, Jacksonville, FL talks to us about a study which examined how patients and their families deal with the diagnosis of an AD-positive biomarker. She reveals what the study found, and explains the likely reason for the result. This interview was recorded at the 2017 Alzheimer’s Association International Conference (AAIC) held in London, UK.
Get great new content delivered to your inboxSign up